MA37961A1 - Nouveaux traitements thérapeutiques par anticorps anti-her2 à basse fucosylation - Google Patents

Nouveaux traitements thérapeutiques par anticorps anti-her2 à basse fucosylation

Info

Publication number
MA37961A1
MA37961A1 MA37961A MA37961A MA37961A1 MA 37961 A1 MA37961 A1 MA 37961A1 MA 37961 A MA37961 A MA 37961A MA 37961 A MA37961 A MA 37961A MA 37961 A1 MA37961 A1 MA 37961A1
Authority
MA
Morocco
Prior art keywords
her2 antibodies
new therapeutic
therapeutic treatments
low fucosylation
fucosylation anti
Prior art date
Application number
MA37961A
Other languages
Arabic (ar)
English (en)
Inventor
Steffen Goletz
Antje Danielczyk
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Publication of MA37961A1 publication Critical patent/MA37961A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention se rapporte au domaine de la cancérothérapie par anticorps anticancéreux. Cette invention, qui fait preuve d'une efficacité accrue, concerne plus particulièrement l'utilisation d'anticorps anti-her2 présentant des caractéristiques de glycosylation améliorées, en particulier une fucosylation réduite..
MA37961A 2012-12-18 2013-07-18 Nouveaux traitements thérapeutiques par anticorps anti-her2 à basse fucosylation MA37961A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12197768 2012-12-18
PCT/EP2013/065189 WO2014013019A1 (fr) 2012-07-18 2013-07-18 Nouveaux traitements thérapeutiques par anticorps anti-her2 à basse fucosylation

Publications (1)

Publication Number Publication Date
MA37961A1 true MA37961A1 (fr) 2016-06-30

Family

ID=49948317

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37961A MA37961A1 (fr) 2012-12-18 2013-07-18 Nouveaux traitements thérapeutiques par anticorps anti-her2 à basse fucosylation

Country Status (16)

Country Link
US (1) US20150166664A1 (fr)
EP (1) EP2874658A1 (fr)
JP (1) JP2015528802A (fr)
KR (1) KR20150036710A (fr)
CN (1) CN104394887A (fr)
AU (1) AU2013291964B2 (fr)
BR (1) BR112014032169A2 (fr)
CA (1) CA2875486A1 (fr)
EA (1) EA201590237A1 (fr)
IL (1) IL236714A0 (fr)
MA (1) MA37961A1 (fr)
MX (1) MX2015000730A (fr)
NZ (1) NZ701974A (fr)
SG (1) SG11201407841YA (fr)
WO (1) WO2014013019A1 (fr)
ZA (1) ZA201408938B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU92659B1 (en) * 2015-02-23 2016-08-24 Glycotope Gmbh Glycooptimized antibody drug conjugates
JP2020512382A (ja) * 2017-03-29 2020-04-23 グリコトープ ゲーエムベーハー Ｐｄ−ｌ１抗体およびｔａ−ｍｕｃ１抗体
CN112566667B (zh) * 2018-06-15 2023-06-09 上海美雅珂生物技术有限责任公司 治疗癌症的方法和材料
WO2022022526A1 (fr) * 2020-07-28 2022-02-03 百奥泰生物制药股份有限公司 Anticorps anti-her2 et son utilisation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01007170A (es) 1999-01-15 2002-07-30 Genentech Inc Variantes de polipeptidos con funcion efectora alterada.
EP2275540B1 (fr) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Procédé de contrôle de l'activité de molécule fonctionnelle immunologique
CA2412701A1 (fr) 2000-06-28 2002-01-03 Glycofi, Inc. Procede de production de glycoproteines modifiees
JP2005532253A (ja) 2001-10-25 2005-10-27 ジェネンテック・インコーポレーテッド 糖タンパク質組成物
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament
SG2013005590A (en) * 2003-01-22 2015-06-29 Roche Glycart Ag Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
JPWO2005053742A1 (ja) * 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
WO2005086875A2 (fr) * 2004-03-11 2005-09-22 City Of Hope Anticorps t84.66 anti-ace humanise et ses applications
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
CA2662226C (fr) * 2006-09-10 2020-08-04 Glycotope Gmbh Systeme de production a haut rendement, entierement humain, pour anticorps et proteines ameliores
TR201804897T4 (tr) * 2009-10-07 2018-06-21 Macrogenics Inc Fukosi̇lasyon ölçüsünün deği̇şi̇mleri̇nden dolayi geli̇şmi̇ş efektör i̇şlevi̇ sergi̇leyen fc bölgesi̇ni̇ i̇çeren poli̇pepti̇tler ve bunlarin kullanimlarina yöneli̇k yöntemler
US20120258496A1 (en) * 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells

Also Published As

Publication number Publication date
ZA201408938B (en) 2016-09-28
BR112014032169A2 (pt) 2017-08-01
CA2875486A1 (fr) 2014-01-23
IL236714A0 (en) 2015-02-26
WO2014013019A1 (fr) 2014-01-23
SG11201407841YA (en) 2015-02-27
EA201590237A1 (ru) 2015-05-29
KR20150036710A (ko) 2015-04-07
MX2015000730A (es) 2015-08-06
NZ701974A (en) 2018-03-23
EP2874658A1 (fr) 2015-05-27
AU2013291964B2 (en) 2017-12-14
US20150166664A1 (en) 2015-06-18
JP2015528802A (ja) 2015-10-01
AU2013291964A1 (en) 2015-02-05
CN104394887A (zh) 2015-03-04

Similar Documents

Publication Publication Date Title
CO2017005845A2 (es) Anticuerpos monoclonales aislados contra cd73
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
CY1121517T1 (el) Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib
EA201890079A1 (ru) Клеточная система для направленной доставки активного ингредиента
MA40713A1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers
EA201590987A1 (ru) Соединения и способы их применения
MA40813A1 (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre diverses tumeurs
EA201890915A1 (ru) Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
MA43466A1 (fr) Traitements du cancer de l'utérus
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
TN2015000396A1 (en) Antibody drug conjugates
EA201400625A1 (ru) Антитела против pd-l1 и их применение
WO2014160160A3 (fr) Conjugués anticorps-médicaments
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
EA201391416A1 (ru) Новые соединения в качестве модуляторов протеинкиназ
MA37975A1 (fr) Inhibiteurs de synthase de glucosylcéramide
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
WO2015009726A3 (fr) Utilisations médicales d'agonistes de cd38
EA201491447A1 (ru) Ендиины, их конъюгаты и способы их получения и применения
MX2011010673A (es) Formulaciones de nanoparticulas y usos de las mismas.
UA114277C2 (uk) Антиангіогенна терапія для лікування раку яєчника
MA42164B1 (fr) Composes biheteroaryle et leurs utilisations
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
WO2014163714A3 (fr) Conjugués médicament-anticorps
MA32900B1 (fr) Compose d'aminopyrazole